Literature DB >> 20378573

Molecular basis and clonal evolution of myeloproliferative neoplasms.

Roland Jäger, Robert Kralovics.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20378573      PMCID： PMC2857179          DOI： 10.3324/haematol.2009.019570

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  29 in total

Review 1.  Von Recklinghausen's neurofibromatosis: neurofibromatosis type 1.

Authors:  R M Reynolds; G G P Browning; I Nawroz; I W Campbell
Journal:  Lancet       Date:  2003-05-03       Impact factor: 79.321

Review 2.  The Cbl interactome and its functions.

Authors:  Mirko H H Schmidt; Ivan Dikic
Journal:  Nat Rev Mol Cell Biol       Date:  2005-12       Impact factor: 94.444

3.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

4.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

5.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

6.  Nf1 and Gmcsf interact in myeloid leukemogenesis.

Authors:  R A Birnbaum; A O'Marcaigh; Z Wardak; Y Y Zhang; G Dranoff; T Jacks; D W Clapp; K M Shannon
Journal:  Mol Cell       Date:  2000-01       Impact factor: 17.970

7.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

Review 8.  Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders.

Authors:  Robert Kralovics; Radek C Skoda
Journal:  Blood Rev       Date:  2005-01       Impact factor: 8.250

9.  High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations.

Authors:  Frank Stegelmann; Lars Bullinger; Martin Griesshammer; Karlheinz Holzmann; Marianne Habdank; Susanne Kuhn; Carmen Maile; Stefanie Schauer; Hartmut Döhner; Konstanze Döhner
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

10.  Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.

Authors:  G Bollag; D W Clapp; S Shih; F Adler; Y Y Zhang; P Thompson; B J Lange; M H Freedman; F McCormick; T Jacks; K Shannon
Journal:  Nat Genet       Date:  1996-02       Impact factor: 38.330
View more
  6 in total

Review 1.  Genetic Background of Polycythemia Vera.

Authors:  Mathilde Regimbeau; Romain Mary; François Hermetet; François Girodon
Journal:  Genes (Basel)       Date:  2022-04-02       Impact factor: 4.141

2.  Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing.

Authors:  Francisca Ferrer-Marín; Beatriz Bellosillo; Luz Martínez-Avilés; Gloria Soler; Pablo Carbonell; Ginés Luengo-Gil; Eva Caparrós; José M Torregrosa; Carlos Besses; Vicente Vicente
Journal:  J Hematol Oncol       Date:  2013-09-08       Impact factor: 17.388

Review 3.  The Role of MicroRNAs in Myeloproliferative Neoplasia.

Authors:  Shaban Alizadeh; Seyed Ghader Azizi; Masoud Soleimani; Yadollah Farshi; Zahra Kashani Khatib
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2016-07-01

4.  Resveratrol induces cell cycle arrest and apoptosis in malignant NK cells via JAK2/STAT3 pathway inhibition.

Authors:  Ly Quoc Trung; J Luis Espinoza; Akiyoshi Takami; Shinji Nakao
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

5.  Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia.

Authors:  Leonardo Caires Dos Santos; Juliana Corrêa da Costa Ribeiro; Neusa Pereira Silva; Janete Cerutti; Maria Regina Regis da Silva; Maria de Lourdes Lopes Ferrari Chauffaille
Journal:  Rev Bras Hematol Hemoter       Date:  2011

Review 6.  Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.

Authors:  Javier Pinilla-Ibarz; Kendra L Sweet; Gabriela M Corrales-Yepez; Rami S Komrokji
Journal:  Onco Targets Ther       Date:  2016-08-10       Impact factor: 4.147
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.